Fri, Nov 22, 2024
Volume 16, Issue 6 (Special issue (Nov-Dec) 2022)
mljgoums 2022, 16(6): 40-44 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Astagimath M, Doddamani S, Patil V, Aryapu R. Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine. mljgoums 2022; 16 (6) :40-44
URL: http://mlj.goums.ac.ir/article-1-1497-en.html
URL: http://mlj.goums.ac.ir/article-1-1497-en.html
1- Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India
2- Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi Karnataka, India
3- Assistant Professor,Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India. ,vcpatil2009@gmail.com
4- Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India
2- Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi Karnataka, India
3- Assistant Professor,Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India. ,
4- Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India
Abstract: (2512 Views)
Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination.
Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack.
Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24).
Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.
Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack.
Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24).
Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.
Research Article: Original Paper |
Subject:
Immunology
Received: 2022/03/16 | Accepted: 2022/06/1 | Published: 2022/09/6 | ePublished: 2022/09/6
Received: 2022/03/16 | Accepted: 2022/06/1 | Published: 2022/09/6 | ePublished: 2022/09/6
References
1. Branswell H, Joseph A. WHO declares the coronavirus outbreak a pandemic. [cited 2021 Dec 31]. [View at Publisher]
2. COVID-19 CORONAVIRUS PANDEMIC [Internet]. [cited 2021 Dec 31] [View at Publisher]
3. Statistics from WHO's Global Health Observatory [Internet]. [cited 2021 Dec 31] [View at Publisher]
4. Jeald Sadoff, Gelenda Gray, An Vandebosch,Vicky Cardenas. Safety and efficacy of single dose Ad26.COV2.SVaccine against Covid-19. N Engl J Med. 2021; 384: 2187-2201. [View at Publisher] [DOI:10.1056/NEJMoa2101544]
5. Livingston EH. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines. JAMA. 2021; 325(9): 898. [View at Publisher] [DOI:10.1001/jama.2021.1375] [PubMed] [Google Scholar]
6. Binay U, Karakecili F, Binali E, Barkay O, Gul O, Mertoglu C. Level of SARS-CoV-2 IgG antibodies after two doses CoronaVac vaccine: Primarily report. Journal of Antivirals & Antiretroviral. 2021; 13; S18:004. [View at Publisher] [DOI:10.21203/rs.3.rs-388073/v2] [Google Scholar]
7. Chang KP. Vaccination for Disease Prevention and Control: the Necessity of Renewed Emphasis and New Approaches. J Immunol Immunotech. 2014; 1(1):10.17653/2374-9105.SSe0001. [View at Publisher] [DOI:10.17653/2374-9105.SSe0001] [PubMed] [Google Scholar]
8. Min L, Sun Q. Antibodies and Vaccines Target RBD of SARS-CoV-2. Front Mol Biosci. 2021: 671633. [View at Publisher] [DOI:10.3389/fmolb.2021.671633] [PubMed] [Google Scholar]
9. Victor PJ, Mathews KP, Paul H, Mammen JJ, Murugesan M. Protective Effect of COVID-19 Vaccine Among Health Care Workers During the Second Wave of the Pandemic in India. Mayo Clinic proceedings. 2021; 96(9): 2493-2494. [View at Publisher] [DOI:10.1016/j.mayocp.2021.06.003] [PubMed] [Google Scholar]
10. Hall VJ, Foulkes S, Saei A, Andrews N, Oguti B, Charlett A, et al. COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study. Lancet. 2021; 397(10286): 1725-35. [View at Publisher] [DOI] [PubMed] [Google Scholar]
11. Parry H, Bruton R, Stephens C, Brown K, Amirthalingam G, Hallis B, et al. Extended interval BNT162b2 vaccination enhances peak antibody generation. npj Vaccines. 2022,7:14. [View at Publisher] [DOI:10.1038/s41541-022-00432-w] [PubMed] [Google Scholar]
12. Lo Sasso B, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, et al. Evaluation of anti-sars-cov-2 s-rbd igg antibodies after covid-19 mrna bnt162b2 vaccine. Diagnostics. 2021;11(7):1-9. [View at Publisher] [DOI:10.3390/diagnostics11071135] [PubMed] [Google Scholar]
13. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021; 12(1): 844. [View at Publisher] [DOI:10.1038/s41467-021-23128-6] [PubMed] [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Enamad
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.